Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models

Based on the previously described roles of doxorubicin in immunogenic cell death, both doxorubicin and liposomal doxorubicin (Doxil) were evaluated for their ability to boost the antitumor response of different cancer immunotherapies including checkpoint blockers (anti–PD-L1, PD-1, and CTLA-4 mAbs)...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jonathan Rios-Doria, Nicholas Durham, Leslie Wetzel, Raymond Rothstein, Jon Chesebrough, Nicholas Holoweckyj, Wei Zhao, Ching Ching Leow, Robert Hollingsworth
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2015-08-01
coleção:	Neoplasia: An International Journal for Oncology Research
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S1476558615001001
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!